Insai is developing an AI-based neurotechnology platform focused on converting sleep and EEG data into objective biomarkers for life sciences. The company positions its work within neuroinformatics, biomarker development, and clinical research infrastructure rather than as a primary neuromodulation hardware business. Its public materials frame the platform around research, pharma, and clinical development use cases.

The platform analyzes sleep and EEG recordings using foundation models that extract structured outputs such as sleep architecture, spectral biomarkers, and event markers. Insai also references EEG wearables, including headband and ear-EEG formats, alongside analysis of existing PSG and legacy EEG data, suggesting a cross-device biomarker approach rather than a single-device product. The system is presented as generating automated reports and data outputs for research workflows and regulatory-facing programs.

Insai’s technology is aimed at biopharma, clinical research teams, and other life sciences groups working with neurophysiology data. The platform is intended for research and drug development use rather than clinical diagnosis or therapeutic decision-making. Its positioning reflects a broader shift in neurotechnology toward scalable computational layers built on EEG, sleep, and related physiological datasets.